LHG wins funding to promote NICE approved medicines for Lipid Management
Lakeside Healthcare Group is one of three East Midlands NHS organisations sharing grant money of more than £400,000 to promote targeted medication for specific conditions.
With the support of the East Midlands Academic Health Science Network, we submitted a successful bid for NHS Pathway Funding for the Rapid Uptake Products programme. Our share, totalling more than £100,000, has been awarded for lipid management, one of the clinical priorities in the NHS’s long term plan. The funding can cover set up costs, staff training or specialist clinicians and we will submit detailed findings on the outcome of the year-long project.
Others to have been awarded funding include Nottingham University Hospitals NHS Trust and Chesterfield and Dronfield Primary Care Network.
Kate Dawson, Head of Medicine Pathways and Safety at EMAHSN said: ‘We are delighted that three of our East Midlands projects were awarded the Pathway Transformation Funding and particularly to have been so successful on our bids to improve lipid management to help reduce cholesterol and reduce the number of deaths from heart disease in the East Midlands.’
Dr Miles Langdon, Chief Medical Officer at Lakeside Healthcare Group, said: ‘This is great news for our staff and the Group as a whole. The funding will enable us to give targeted support to key groups of patients across our practices to improve their health and wellbeing. We are delighted to work so closely with colleagues at EMAHSN to support this key priority area and shape future clinical practice.’
Published: Jul 1, 2021